Treatment with the anti-CSF-1R antibody pexidartinib (PLX3397) significantly reduces GL261-associated GAM infiltration and inhibits M2 polarization, thereby inhibiting glioma growth (135). The gene discussed is CSF1R; the disease is central nervous system cancer.